Literature DB >> 19882553

Role of antibiotic lock therapy for the treatment of catheter-related bloodstream infections.

Jose L del Pozo1.   

Abstract

Catheter-related bloodstream infections are often difficult to treat because they are caused by organisms that embed themselves in a biofilm layer on the catheter surface, resulting in an increased resistance to antimicrobial agents. Systemic antibiotics are usually administered but, although generally effective in eliminating circulating bacteria, they frequently fail to sterilize the line, leaving the patient at a continuing risk of complications or recurrence. A successful approach to managing these infections requires making an appropriate decision regarding whether the catheter should be removed or retained using antibiotic lock therapy; and choosing the type and duration of antimicrobial therapy based on the type of organism and its resistance pattern. Studies that have evaluated antibiotic lock therapy have varied in the types of antibiotics and concentrations used, the addition of heparin to the solutions, and dwell times in the catheter lumen. Guidelines from the Infectious Diseases Society of America include use of antibiotic lock therapy as a therapeutic option for intraluminal infections when the device is not removed and, although not routine, as prophylaxis for catheter-related infection in select patient populations. However, there are no published guidelines on the concentration of heparin or antibiotics that should be used, and minimal published data on the stability of heparin combinations with antibiotics. It is to be hoped that antibiotic locks will be subject to randomized controlled trials of sufficient power to confirm or refute their use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19882553     DOI: 10.1177/039139880903200918

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  7 in total

1.  Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter.

Authors:  P Tatarelli; A Parisini; V Del Bono; M Mikulska; C Viscoli
Journal:  Infection       Date:  2014-08-12       Impact factor: 3.553

2.  Antimicrobial and anticoagulant activities of N-chlorotaurine, N,N-dichloro-2,2-dimethyltaurine, and N-monochloro-2,2-dimethyltaurine in human blood.

Authors:  C Martini; A Hammerer-Lercher; M Zuck; A Jekle; D Debabov; M Anderson; M Nagl
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

3.  High-Dose Daptomycin Is Effective as an Antibiotic Lock Therapy in a Rabbit Model of Staphylococcus epidermidis Catheter-Related Infection.

Authors:  Benito Almirante; Joan Gavaldà; Jana Basas; Marta Palau; Carlos Ratia; José L Del Pozo; María Teresa Martín-Gómez; Xavier Gomis; Eduard Torrents
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Current strategies for the prevention and management of central line-associated bloodstream infections.

Authors:  Zhuolin Han; Stephen Y Liang; Jonas Marschall
Journal:  Infect Drug Resist       Date:  2010-11-23       Impact factor: 4.003

5.  Eradication of P. aeruginosa biofilm in endotracheal tubes based on lock therapy: results from an in vitro study.

Authors:  María Jesús Pérez-Granda; María Consuelo Latorre; Beatriz Alonso; Javier Hortal; Rafael Samaniego; Emilio Bouza; María Guembe
Journal:  BMC Infect Dis       Date:  2017-12-04       Impact factor: 3.090

6.  EDTA and Taurolidine Affect Pseudomonas aeruginosa Virulence In Vitro-Impairment of Secretory Profile and Biofilm Production onto Peritoneal Dialysis Catheters.

Authors:  Bruna Colombari; Gaetano Alfano; Christian Gamberini; Gianni Cappelli; Elisabetta Blasi
Journal:  Microbiol Spectr       Date:  2021-11-17

Review 7.  Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors.

Authors:  Ondřej Kubeček; Pavla Paterová; Martina Novosadová
Journal:  Life (Basel)       Date:  2021-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.